DATE: 09 Nov 2023
CATEGORY: PRESS RELEASE
Ichnos Sciences Data Selected For Presentation at the 65th ASH Annual Meeting
Three poster presentations on three oncology assets, including clinical data on ISB 1342 and ISB 1442, and trial-in-progress data on ISB 2001.
FOR IMMEDIATE RELEASE
NEW YORK, NY
November 9, 2023
NEW YORK, November 9, 2023 – Ichnos Sciences, a global clinical-stage biotechnology company developing innovative multispecific antibodies for oncology, today announced that three abstracts highlighting data on its leading oncology assets have been selected for presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting will be held December 9-12, 2023, in San Diego, California.
These abstracts discuss three assets—ISB 2001, ISB 1342 and ISB 1442—each of which have been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma and are currently in global Phase 1 clinical studies. The data to be presented will demonstrate the innovative approach of Ichnos’ proprietary BEAT® platform1 to target tumor cells via the engagement of different immune cell subtypes. This approach holds promise to be a curative therapy for patients experiencing relapsed or refractory multiple myeloma who need new treatment options.
“Ichnos’ work is built on a foundation of believing a cure is attainable and recognizing that there is a wide space in oncology for original thinking when it comes to developing efficient, disease-specific treatments,” said Lida Pacaud, M.D., Chief Medical Officer of Ichnos Sciences. “Our scientific platform leverages the power of the human immune system in the fight against cancer, and we are glad to be granted the opportunity to share our data on this approach thus far at the upcoming ASH Annual Meeting.”
Visit the Ichnos Sciences booth (#305) at the ASH Annual Meeting to learn more about Ichnos’ proprietary BEAT® platform, expanding pipeline of assets in hematological and solid tumor malignancies, partnership opportunities and more.
More information about Ichnos presentations is detailed below:
|Details (All in Pacific Time)
|Poster Presentation: Trial in Progress: A Phase 1, First-in-Human, Dose Escalation and Dose-Expansion Study of a BCMAxCD38xCD3 Targeting Trispecific Antibody ISB 2001 in Subjects with Relapsed / Refractory Multiple Myeloma (RRMM)
|Sunday, December 10, 2023, 6:00 PM-8:00 PM San Diego Convention Center, Halls G-H Session: 653. Multiple Myeloma: Prospective Therapeutic Trials: Poster II Publication Number: 3396
|Poster Presentation: Dose Escalation of ISB 1342, a Novel CD38xCD3 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
|Sunday, December 10, 2023, 6:00 PM-8:00 PM San Diego Convention Center, Halls G-H Session Name: 652. Multiple Myeloma: Clinical and Epidemiological: Poster II Publication Number: 3339
|Poster Presentation: Initial Results From the Dose Escalation Phase1/2 of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
|Monday, December 11, 2023, 6:00 PM-8:00 PM San Diego Convention Center, Halls G-H Session Name: 652. Multiple Myeloma: Clinical and Epidemiological: Poster III Publication Number: 4707
The full ASH 2023 Annual Meeting abstracts are available for review at: https://www.hematology.org/meetings/annual-meeting/abstracts
Follow Ichnos on LinkedIn for more updates throughout the conference.
About Ichnos Sciences Inc.
A fully integrated, global biotech with the spirit of a start-up, Ichnos is shifting the way the world thinks about innovation in medicine through its research and development of transformative, disease-centric treatments in oncology. The company, with headquarters in New York, N.Y., is rapidly advancing a clinical-stage pipeline of novel, first-in-class candidates designed to address complex diseases and to treat patients holistically. With its patented BEAT® technology platform and pioneering teams, Ichnos Sciences has a mission to provide breakthrough, curative therapies that will extend and improve lives, writing a new chapter in healthcare.
For more information, visit Ichnos.com.
C O N T A C T
Hill & Knowlton
1BEAT®: Bispecific Engagement by Antibodies based on the TCR